Cell Therapy Raw Materials Market Size & Growth Report to 2030

The global cell therapy raw materials market size was accounted at around USD 5 billion in 2024 and anticipated to register a robust CAGR of around 20% during the forecast period from 2025 to 2030. The market is driven by the growing demand for regenerative medicine and personalized therapies. Raw materials such as culture media, cytokines, growth factors, scaffolds, and cell separation reagents are crucial for the production and development of cell-based therapies. As the prevalence of chronic diseases and conditions such as cancer, cardiovascular diseases, and autoimmune disorders rise, the need for advanced treatment options like stem cell therapies and tissue engineering is expanding. The increasing focus on personalized medicine also boosts the demand for specific and tailored raw materials for individual patient therapies. Furthermore, advancements in biotechnology, improvements in GMP (Good Manufacturing Practices) standards, and the rise of cell and gene therapies contribute to the growth of this market.

Regionally, North America holds a significant share due to its robust healthcare infrastructure, advanced biotechnology research, and high adoption rate of regenerative medicine. Europe follows closely, supported by government funding and research initiatives in the field of cell therapy. The Asia-Pacific region is expected to see rapid growth due to improving healthcare systems, increased investments in biotechnology, and a growing aging population. The market is also influenced by strategic collaborations and partnerships between raw material suppliers, biotechnology companies, and research institutions, all of which help to drive innovation and enhance the availability of quality raw materials.

Market Snapshot:

Market Drivers:

The global cell therapy raw materials market is experiencing significant growth, driven by several key factors. The increasing prevalence of chronic diseases such as cancer, diabetes, and autoimmune disorders has heightened the demand for advanced therapeutic solutions, thereby boosting the need for raw materials essential in cell therapy production. Advancements in biotechnology, including the development of three-dimensional cell culture techniques and aseptic processing methods, have enhanced the efficiency and scalability of cell-based therapies. These innovations not only improve therapeutic outcomes but also reduce production costs, making treatments more accessible to a broader patient population.

A notable recent development underscoring this trend is the introduction of Lonza’s TheraPEAK T-VIVO cell culture medium in May 2023. This serum-free and animal component-free medium supports safe and consistent cell therapy manufacturing, reflecting the industry’s shift towards chemically defined formulations that enhance safety, traceability, and regulatory compliance. Such innovations not only help to minimize the risk of contamination and batch variability but also streamline the approval process for therapies in clinical trials. Moreover, the increasing number of regulatory approvals for cell-based therapies and the rising investment by pharmaceutical and biotech companies in cell therapy manufacturing facilities further amplify the demand for advanced raw materials. These factors collectively contribute to the market’s robust growth trajectory, positioning it as a critical component in the future of personalized and regenerative medicine.

Market Trends:

Shift Towards Chemically Defined Media

One of the most prominent trends in the market is the increasing transition from animal-derived components to chemically defined, serum-free, and xeno-free media. This shift is crucial for ensuring consistency, reducing the risk of contamination, and enhancing regulatory compliance in cell therapy manufacturing. Chemically defined media provide better control over the components involved in cell culture, resulting in more predictable and reproducible results. As regulatory agencies and manufacturers place greater emphasis on product safety and traceability, the demand for high-quality, defined raw materials is surging, especially in large-scale commercial production of cell therapies.

Advancements in 3D Cell Culture Technology

Three-dimensional (3D) cell culture systems are gaining popularity because they more closely mimic the natural environment of cells in the human body compared to traditional two-dimensional (2D) systems. This advancement has significantly improved the growth, interaction, and differentiation of cells used in therapy. The emergence of 3D bioreactors, scaffolds, and hydrogels is expanding the capabilities of researchers to culture more complex tissue-like structures. These innovations are especially important in areas such as stem cell therapy and tissue engineering, where mimicking real physiological conditions is vital for treatment efficacy, thereby driving up the demand for compatible and advanced raw materials.

Growing Focus on Personalized Medicine

The movement toward personalized medicine has led to a growing need for customized raw materials that are specifically designed for individual patient profiles and therapeutic needs. In cell therapy, this often involves autologous approaches where a patient’s own cells are used to develop the treatment. This requires specialized reagents, media, and processing tools that can accommodate variations in cell types and donor characteristics. As precision medicine becomes more central in modern healthcare, the demand for raw materials that support flexible and adaptive manufacturing processes is increasing rapidly.

Rising Investments and Strategic Partnerships

There has been a notable rise in global investments from both private companies and public organizations aimed at accelerating cell therapy research and commercialization. Pharmaceutical and biotechnology firms are forming strategic collaborations with raw material suppliers to enhance product quality, reduce time-to-market, and ensure supply chain security. These partnerships are helping to develop innovative materials, streamline production workflows, and integrate new technologies into existing platforms. Increased funding for cell and gene therapy manufacturing infrastructure also reinforces the demand for a reliable supply of raw materials.

Regulatory Advancements and Standardization

Regulatory bodies such as the FDA (U.S. Food and Drug Administration) and EMA (European Medicines Agency) are increasingly focusing on establishing clear and standardized guidelines for cell therapy products, including the raw materials used. These evolving frameworks aim to ensure the safety, efficacy, and quality of therapies from early development through commercialization. As a result, manufacturers are investing more in GMP-compliant raw materials and quality control systems. The greater emphasis on traceability and documentation is pushing suppliers to offer well-characterized and validated materials that meet stringent quality standards.

Market Opportunities:

The global cell therapy raw materials market is witnessing significant growth opportunities, driven by the expansion of personalized medicine and advancements in bioprocessing technologies. The increasing demand for tailored cell therapies necessitates the development of customized raw materials that cater to specific patient and therapy requirements. Innovations in bioprocessing, such as perfusion bioreactors and microcarrier-based systems, are creating opportunities for the introduction of raw materials designed for these evolving manufacturing approaches. Additionally, the global expansion of cell therapy manufacturing facilities underscores the growing need for high-quality raw materials to support large-scale therapy production.​

The rising prevalence of chronic diseases in the United States further amplifies the demand for advanced cell therapies. According to the Centers for Disease Control and Prevention (CDC), approximately 129 million Americans are living with at least one major chronic disease, such as heart disease, cancer, or diabetes. Notably, 42% of these individuals have two or more chronic conditions, and 12% are managing five or more. These chronic diseases account for about 90% of the nation’s annual healthcare expenditure, highlighting the substantial economic burden and the urgent need for innovative treatment solutions. As the healthcare industry seeks more effective and personalized treatment options, the demand for high-quality raw materials essential for cell therapy development is expected to rise correspondingly.

Market Segment Insights:

By Product:

The global cell therapy raw materials market is bifurcated into product, end-use, and geography. On the basis of product, the media segment is the dominant product category in the global market in 2024. Media plays a vital role in providing the necessary nutrients, growth factors, and environmental conditions that cells require for optimal growth, differentiation, and expansion. As cell therapies, particularly stem cell and immunotherapy treatments like CAR-T (chimeric antigen receptor T-cell) therapies, continue to evolve, the need for advanced media formulations is on the rise. The market is experiencing a shift toward chemically defined, serum-free, and xeno-free media solutions to address concerns related to variability, contamination, and regulatory approval. These specialized media are crucial for ensuring consistent and reproducible results in cell therapy production, further driving the market’s growth in this segment.

Additionally, with the global push toward personalized medicine and precision therapies, the demand for customized media that can support a wide range of cell types is increasing. The ability to tailor media formulations to specific therapeutic needs enhances their efficacy and supports the scalability of manufacturing processes. As major players in the cell therapy market, such as Lonza, Sartorius, and Thermo Fisher, continue to innovate and expand their product portfolios to meet these requirements, the media segment is expected to maintain its dominance. Furthermore, the rise of GMP-compliant and highly defined media formulations that align with regulatory standards provides a solid foundation for the ongoing growth and adoption of cell therapies in clinical and commercial settings.

By End-Use:

On the basis of end-use, the global cell therapy raw materials market is further segmented into biopharmaceutical & pharmaceutical companies, CROs & CMOs, and others. In 2024, the biopharmaceutical & pharmaceutical companies segment is the dominant category in the global market. This dominance is primarily due to the substantial investments made by pharmaceutical companies in developing and commercializing cell therapies, including immunotherapies like CAR-T (Chimeric Antigen Receptor T-cell) therapies and stem cell treatments. As these therapies move from research into clinical development and commercialization, the demand for high-quality raw materials such as specialized cell culture media, growth factors, cytokines, and antibodies increases. Biopharmaceutical companies are at the forefront of ensuring that these therapies are safe, scalable, and effective, which requires the use of premium raw materials that meet rigorous regulatory and quality standards. The rapid growth of the cell therapy pipeline and the increasing number of clinical trials are contributing to the market’s expansion within this segment.

Moreover, the rise of personalized medicine, which tailors treatments based on an individual’s genetic makeup, is driving the need for more specialized raw materials to support the development of targeted therapies. Biopharmaceutical companies, as the key players in the commercialization of these therapies, are focused on ensuring the reproducibility and consistency of the manufacturing process, which heavily relies on high-quality raw materials. The continued advancements in cell-based therapies and the increase in demand for these innovative treatments further solidify the importance of biopharma companies in the market, making them the dominant segment in the cell therapy raw materials market. As more therapies receive approval, the need for raw materials to support mass production is expected to keep growing, reinforcing the dominance of this segment.

The cell therapy raw materials market research report presents the analysis of each segment from 2020 to 2030 considering 2023 as the base year for the research. The compounded annual growth rate (CAGR) for each respective segment is calculated for the forecast period from 2025 to 2030.

Historical & Forecast Period

• 2020-23 – Historical Year
• 2024 – Base Year
• 2025-2030 – Forecast Period

Market Segmentation:

By Product:

• Media
• Antibodies
• Sera
• Cell Culture Supplements
• Reagents & Buffers
• Others

By End-Use:

• Biopharmaceutical & Pharmaceutical Companies
• CROs & CMOs
• Others

By Region:

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Regional Analysis:

Geographically, the North America is the dominant region in the global cell therapy raw materials market, holding a significant revenue share of approximately 1/2 of the global market in 2024. This leadership is driven by a combination of factors that position North America at the forefront of the cell therapy industry. The region boasts a strong and well-established healthcare infrastructure, which is critical for the rapid adoption and scaling of cutting-edge therapies. The United States, in particular, is home to numerous biopharmaceutical giants and innovative biotech startups that are heavily involved in the development and commercialization of cell therapies. These companies are working on groundbreaking treatments for cancer, autoimmune diseases, and genetic disorders, all of which rely heavily on high-quality raw materials like cell culture media, cytokines, and growth factors. Additionally, the region’s supportive regulatory framework, spearheaded by organizations like the FDA, facilitates the approval and commercialization of new therapies, making it an attractive environment for innovation and manufacturing.

The dominance of North America is also supported by continuous investments in biotechnology and biomanufacturing, which help to strengthen the production capabilities of cell therapy raw materials. For example, in October 2024, Johnson & Johnson announced an investment of over $2 billion to build a state-of-the-art biologics manufacturing facility in Wilson, North Carolina. This new facility will significantly increase the production capacity for biologics, including cell-based therapies, and will play a pivotal role in the region’s ability to meet the rising demand for advanced therapies. Such investments indicate a strong commitment to enhancing manufacturing capabilities, ensuring that raw materials for cell therapies are produced in large quantities while maintaining the highest quality standards. This, in turn, strengthens North America’s leadership position in the global market. As the demand for cell-based therapies continues to rise, the region’s infrastructure and investment in advanced technologies will further bolster its dominance in the cell therapy raw materials market.

Competitive Landscape:

Some of the leading market players operating in the global cell therapy raw materials market are Thermo Fisher Scientific Inc., Merck KGaA, Danaher, Sartorius Stedim Biotech, and Actylis. Companies are exploring markets by expansion, new investment, the introduction of new services, and collaboration as their preferred strategies. Players are exploring new geography through expansion and acquisition to gain a competitive advantage through joint synergy.

Recent Developments:

• In December 2024, at Advanced Therapies Week 2025, PHC Corporation of North America will unveil a prototype of its LiCellGrow cell expansion device. This innovative technology, currently under development, aims to revolutionize the production of gene and cell therapies by providing real-time insights into cellular metabolic processes, enhancing the efficiency and precision of these therapies.
• In December 2024, BioCentriq signed a long-term lease for a new manufacturing facility in Princeton, NJ, which will also serve as its headquarters. With an investment of USD 12 million, this facility will significantly boost BioCentriq’s capabilities in the development and production of cell therapies, supporting its growth in this rapidly expanding market.
• In December 2023, FUJIFILM Corporation announced a USD 200 million investment aimed at significantly increasing its global contract development and manufacturing (CDMO) capabilities for cell therapy. This investment will be allocated to two of Fujifilm’s subsidiaries, enabling the company to support the fast-growing cell therapy market, which is projected to grow from USD 3.3 billion in FY2022 to expand at a rate of over 30% annually.

Key Companies:

• Thermo Fisher Scientific Inc.
• Merck KGaA
• Danaher
• Sartorius Stedim Biotech
• Actylis
• ACROBiosystems
• STEMCELL Technologies.
• Grifols, S.A.
• Charles River Laboratories
• RoosterBio, Inc.
• PromoCell GmbH

Key Questions Answered by Cell Therapy Raw Materials Market Report

• Global cell therapy raw materials market forecasts from 2025-2030
• Regional market forecasts from 2025-2030 covering Asia-Pacific, North America, Europe, Middle East & Africa, and Latin America
• Country-level forecasts from 2025-2030 covering 15 major countries from the regions as mentioned above
• Cell therapy raw materials submarket forecasts from 2025-2030 covering the market by product, end-use, and geography
• Various industry models such as SWOT analysis, Value Chain Analysis about the market
• Analysis of the key factors driving and restraining the growth of the global, regional, and country-level cell therapy raw materials markets from 2025-2030
• Competitive Landscape and market positioning of top 10 players operating in the market